Aura Biosciences, Inc. (NASDAQ:AURA) Shares Purchased by Levin Capital Strategies L.P.

Levin Capital Strategies L.P. grew its holdings in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 169.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,247,619 shares of the company's stock after buying an additional 783,984 shares during the period. Levin Capital Strategies L.P. owned 2.50% of Aura Biosciences worth $10,255,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Charles Schwab Investment Management Inc. increased its position in Aura Biosciences by 2.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company's stock worth $1,233,000 after purchasing an additional 3,612 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Aura Biosciences during the fourth quarter worth about $87,000. State Street Corp increased its position in Aura Biosciences by 3.7% during the third quarter. State Street Corp now owns 754,803 shares of the company's stock worth $6,725,000 after purchasing an additional 26,841 shares during the last quarter. JPMorgan Chase & Co. increased its position in Aura Biosciences by 107.5% during the third quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company's stock worth $477,000 after purchasing an additional 27,718 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Aura Biosciences by 4.1% during the third quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company's stock worth $8,990,000 after purchasing an additional 39,379 shares during the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insiders Place Their Bets

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the business's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the sale, the insider now directly owns 304,692 shares in the company, valued at $2,336,987.64. The trade was a 4.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last ninety days, insiders have sold 23,045 shares of company stock worth $177,242. Corporate insiders own 5.40% of the company's stock.

Aura Biosciences Price Performance

Shares of NASDAQ AURA traded down $0.01 during trading on Wednesday, hitting $7.49. 231,277 shares of the company were exchanged, compared to its average volume of 181,688. The company has a market cap of $374.13 million, a price-to-earnings ratio of -4.33 and a beta of 0.29. Aura Biosciences, Inc. has a 1 year low of $6.63 and a 1 year high of $12.38. The firm's fifty day moving average price is $7.83 and its 200 day moving average price is $8.69.

Analyst Upgrades and Downgrades

AURA has been the subject of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $22.00 target price on shares of Aura Biosciences in a research note on Thursday, November 14th. Lifesci Capital raised shares of Aura Biosciences to a "strong-buy" rating in a research note on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.